AIM ImmunoTech Inc. (AIM)
NYSE: AIMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Pre-market: 0.1818 +0.28%
AIM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.17M
- EPS (TTM)
- -$3.03
- Dividend yield
- None
- 52-week range
- 0.17 – 2.79
- Day range
- 0.177 – 0.185
- Volume / Avg
- 450.95K / 4.70M
- Beta
- —
- Shares outstanding
- 39.89M
52-week range
AIM stock today
Shares of AIM ImmunoTech (AIM) finished lower on Oct 8 at $0.1796, a drop of 1.75% or $0.0032 per share, versus the S&P 500's 0.47% decline. Trading was light, with 450.95K shares changing hands, about 10% of the average daily volume. Shares are 93.6% below their 52-week high of $2.79 and 5.6% above the 52-week low of $0.17, near the bottom of the past year's range.
AIM ImmunoTech has posted a net loss over the last twelve months (EPS of -$3.03), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About AIM ImmunoTech
Company profileAIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Thomas K. Equels Esq., J.D., M.S.
- Headquarters
- Ocala, FL
- Employees
- 19
- Website
- aimimmuno.com
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$4.25+2266.37%
- Strong buy 1
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
AIM ImmunoTech peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BTTCBlack Titan Corporation | 0.495 | -3.51% | $6.78M | vs AIM |
| CELZCreative Medical Technology Holdings Inc. | 0.8604 | -2.45% | $6.53M | vs AIM |
| LIMNLiminatus Pharma Inc. Class A | 3.69 | -4.65% | $4.96M | vs AIM |
| SNTISenti Biosciences Holdings Inc. | 0.3217 | -2.52% | $10.02M | vs AIM |
| PMCBPharmaCyte Biotech Inc. | 0.3974 | -2.02% | $4.27M | vs AIM |
| CLDICalidi Biotherapeutics Inc. | 1.04 | +2.97% | $3.82M | vs AIM |
| SLXNSilexion Therapeutics Corp | 0.2349 | -7.37% | $3.40M | vs AIM |
| VIVSVivoSim Labs Inc. | 0.1772 | -7.47% | $2.94M | vs AIM |
Indexes, lists and sector
AIM ImmunoTech stock FAQ
What is AIM ImmunoTech's stock price today?
AIM last traded at $0.1796 as of Oct 8, 4:00 PM EDT, down 1.75% on the day. Prices are delayed at least 15 minutes.
Who is AIM ImmunoTech's CEO?
Mr. Thomas K. Equels Esq., J.D., M.S. is the chief executive officer of AIM ImmunoTech Inc., which has about 19 employees.
What is the AIM 52-week high?
The 52-week high for AIM is $2.79 and the 52-week low is $0.17. The stock is currently 93.6% below its high.